Related Experiment Video
Updated: Jun 17, 2025
06:13
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.1K
A Real-world Study Evaluating the Clinical Factors Associated with the Initial SGLT2 Inhibitor Prescription
Journal of Health Care for the Poor and Underserved
|August 12, 2024
Summary
Patients with type 2 diabetes and high A1c, heart failure, or hypotension history were more likely to receive SGLT2 inhibitors. Sulfonylurea use also predicted prescription of these beneficial diabetes medications.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- American Diabetes Association guidelines recommend SGLT2 inhibitors for type 2 diabetes due to cardio-renal and glycemic benefits.
- Understanding factors influencing SGLT2 inhibitor prescription is crucial for optimizing patient care.
Purpose of the Study:
- To identify clinical factors associated with the initial prescription of SGLT2 inhibitors in type 2 diabetes patients eligible for this therapy.
Main Methods:
- A retrospective case-control study analyzed electronic medical records from July 2021 to December 2022.
- Compared patients who received initial SGLT2 inhibitor prescriptions with those who did not.
Main Results:
- Higher A1c (≥8%), heart failure, history of hypotension, and concurrent sulfonylurea use were significantly associated with SGLT2 inhibitor prescription.
- Odds ratios indicated strong associations: heart failure (19.3), hypotension (11.9), sulfonylureas (6.5), and A1c ≥8% (3.7).
Conclusions:
- Patients with specific clinical profiles, including elevated A1c, heart failure, hypotension history, and sulfonylurea use, are more likely to be prescribed SGLT2 inhibitors.
- Further research is needed on adherence and provider prescribing behaviors to optimize SGLT2 inhibitor utilization.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
185
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
185
01:23Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
01:17Oral Hypoglycemic Agents: Sulfonylureas
198
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
198
01:27Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
01:24Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311
01:06Oral Hypoglycemic Agents: Glinides
150
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
150